OptimizeRx CEO Steve Silvestro Joins Board of Directors

The latest announcement is out from OptimizeRx ( (OPRX) ).

On June 24, 2025, OptimizeRx announced the appointment of its CEO, Steve Silvestro, to the Board of Directors, effective June 20, 2025. Silvestro, who became CEO in March 2025, is expected to enhance leadership and contribute to the company’s strategic initiatives aimed at value creation and strengthening its market position. The Board expressed confidence in Silvestro’s leadership, noting significant progress since he assumed the CEO role, and anticipates that his appointment will support the company’s growth and strategic direction.

The most recent analyst rating on (OPRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.

Spark’s Take on OPRX Stock

According to Spark, TipRanks’ AI Analyst, OPRX is a Outperform.

OptimizeRx’s strong revenue growth and strategic enhancements, particularly the transition to a subscription model, are significant positives. Technical indicators show bullish momentum, supporting a positive outlook. However, profitability challenges and valuation concerns moderate the overall score.

To see Spark’s full report on OPRX stock, click here.

More about OptimizeRx

OptimizeRx is a leading healthcare technology company that redefines how life science brands connect with patients and healthcare providers. The company utilizes AI-driven tools like the Dynamic Audience Activation Platform and Micro-Neighborhood Targeting to deliver timely and relevant engagement. Based in Waltham, Massachusetts, OptimizeRx partners with pharmaceutical and life sciences companies to enhance healthcare outcomes.

Average Trading Volume: 294,333

Technical Sentiment Signal: Buy

Current Market Cap: $238.2M

Learn more about OPRX stock on TipRanks’ Stock Analysis page.